Lantern Pharma wins USPTO notice of allowance for LP-284 blood cancer treatment patent application
LTRN•USPTO allowance for LP-284 treatment patent
Lantern Pharma received a USPTO Notice of Allowance for a method-of-treatment patent covering LP-284 in mantle cell lymphoma and double-hit lymphoma.
Claims include LP-284 as monotherapy or in combinations with other anti-cancer agents, with intravenous or intraperitoneal administration covered.
Once issued, the patent is expected to extend LP-284 protection into 2042, adding to composition-of-matter coverage into 2039.
LP-284 clinical program and market opportunity
LP-284 is in a Phase 1a dose-escalation trial in relapsed or refractory B-cell non-Hodgkin’s lymphomas and solid tumors.
Lantern cited a $4 billion annual global market opportunity for targeted blood cancers, estimating 40,000 to 80,000 patients annually.
